Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
Saved in:
| Published in: | Administrative Law Review |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2011
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
- FDA's New Approval Plan for COVID-19 Vaccines: An Inquiry of "Benefit" Rather than the Statutory Scope of "Safety, Purity, and Potency"?
- Legal Issues in E-Rulemaking
- Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears
- Rulemaking by Ambush: How Prohibitions Against It Became Dead Letters
- Dreamers and the FDA: Article III Standing in Immigration Cases after FDA v. Alliance
- Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development